Our results showed an increase in the risk of breast cancer in individual heterozygous for ERCC2 Asp312Asn with women receiving a menopause substitutive treatment and an increased risk for ovarian cancer with no oral contraceptive uses, and/or BMI > 25. Here, ERCC2 is linked to ovarian cancer.